Expanded Access Program of Surufatinib

Recruiting in Palo Alto (17 mi)

+10 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Hutchison Medipharma Limited

No Placebo Group

Trial Summary

What is the purpose of this trial?

This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical trials in this indication are unsuitable. This EAP is currently available in the US only.

Research Team

Marjo Hahka-Kemppinen, MD

Principal Investigator

Hutchison Medipharma Limited

Eligibility Criteria

Inclusion Criteria

Histologically or cytologically documented, well differentiated, locally advanced or metastatic NETs

The patient or parent/legal guardian (as appropriate) is willing and able to provide informed consent, and where required, the patient is willing to provide assent

≥12 years of age

See 5 more